SCHEMBL7090188

SCHEMBL7090188

COc1cc2c(c(C(C)(C)C)c1)OC(=O)C2=C1Nc2ccccc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 3/20 0.38
MAPT P10636 6/20 0.37
ALDH1A1 P00352 5/20 0.37
CSNK1D P48730 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
CSNK1A1 P48729 2/20 0.37
CSNK1E P49674 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GMNN O75496 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
THPO P40225 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7090186 1.00 ERBB2 (0.38) ERBB2MAPTALDH1A1CSNK1DSMN1; SMN2
SCHEMBL7089048 0.85 ERBB2 (0.43) ERBB2MAPTALDH1A1CSNK1DSMN1; SMN2
SCHEMBL7089049 0.85 ERBB2 (0.43) ERBB2MAPTALDH1A1CSNK1DSMN1; SMN2
SCHEMBL7093590 0.85 ALDH1A1 (0.38) ERBB2MAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL7093589 0.85 ALDH1A1 (0.38) ERBB2MAPTALDH1A1SMN1; SMN2TDP1
SCHEMBL7158271 0.80 CA1 (0.44) ALDH1A1CYP1A2CYP3A4HPGDEGFR
SCHEMBL7092131 0.73 TTR (0.40) MAPTALDH1A1TDP1HPGDMAPK1
SCHEMBL7092128 0.73 TTR (0.40) MAPTALDH1A1TDP1HPGDMAPK1
SCHEMBL30444215 0.71 ALDH1A1 (0.60) MAPTALDH1A1CSNK1DSMN1; SMN2CSNK1A1
SCHEMBL28522383 0.71 ALDH1A1 (0.60) MAPTALDH1A1CSNK1DSMN1; SMN2CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030121113-A1 Oxobenzofuranylide-dihydroindolone NESVADBA PETER (CH) 2003-07-03 US disclosed
US-6503937-B1 Coloring agents for high molecular weight materials such as polymers CIBA SPECIALTY CHEMICALS CORPORATION 2003-01-07 US disclosed
EP-1123289-B1 OXOBENZOFURANYLIDE-DIHYDROINDOLONES CIBA SC HOLDING AG (CH) 2002-11-27 EP disclosed
EP-1123289-A1 OXOBENZOFURANYLIDE-DIHYDROINDOLONE Ciba SC Holding AG (CH) 2001-08-16 EP disclosed
WO-2000024736-A1 OXOBENZOFURANYLIDE-DIHYDROINDOLONE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030121113-A1 Oxobenzofuranylide-dihydroindolone CYP1B1, CYP1A1, ECI1 ERBB2 1489/4885MAPT 4204/4885ALDH1A1 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.